(Alliance News) - AstraZeneca PLC on Sunday announced results from the phase 3 trial of its Baxdrostat treatment which showed a statistically significant reduction in the systolic blood pressure of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback